Detalles de la búsqueda
1.
Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma.
Br J Haematol
; 180(3): 365-373, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29193021
2.
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.
Cancer Immunol Immunother
; 65(12): 1533-1544, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27714434
3.
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2.
J Investig Med
; 2021 Feb 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33542072
4.
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.
J Immunother Cancer
; 7(1): 49, 2019 02 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-30777131
5.
Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM.
Clin Genitourin Cancer
; 15(1): 31-41.e4, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27916626
Resultados
1 -
5
de 5
1
Próxima >
>>